Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Published:2021-06 Issue: Volume:Volume 13 Page:465-473
ISSN:1178-6981
Container-title:ClinicoEconomics and Outcomes Research
language:en
Short-container-title:CEOR

Author:

Slavcev Mary,Spinelli Allison,Absalon Elisabeth,Masterson Tara^ORCID,Heuck Christoph,Lam Annette,De Cock Erwin

Publisher

Informa UK Limited

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Reference38 articles.

1. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis

2. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life

3. Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study

4. Quality of life in multiple myeloma: considerations and recommendations

5. Effect of Genetic and Laboratory Findings on Clinical Course of Antisynthetase Syndrome in a Hungarian Cohort

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe;Patient Preference and Adherence;2024-09

2. Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial);JCO Oncology Practice;2024-07-19

3. Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective;Future Oncology;2024-06-24

4. Evaluating unmet needs in large-volume subcutaneous drug delivery: U.S. payer perspectives on a novel, large-volume on-body delivery system;Current Medical Research and Opinion;2024-05-17

5. Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume;mAbs;2023-11-27